EUCTR2011-006332-23-IT进行中（未招募）不适用
PHASE II RANDOMIZED STUDY OF MAINTENANCE TREATMENT WITH BEVACIZUMAB OR BEVACIZUMAB PLUS METRONOMIC CHEMOTHERAPY AFTER FIRST-LINE INDUCTION FOLFOXIRI PLUS BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER PATIENTS - MOMA
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ARCO
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically proven diagnosis of colorectal cancer. •Not resectable metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease. •At least one measurable lesion according to RECIST criteria. •Male or female of 18-75 years of age. •ECOG PS < 2 if aged < 71 years, ECOG PS = 0 if aged 71-75 years; •Life expectancy of at least 12 weeks. •Previous adjuvant chemotherapy containing oxaliplatin is allowed if more than 12 months have elapsed between the end of adjuvant therapy and first relapse; •Previous adjuvant chemotherapy with fluoropyrimidine monotherapy is allowed if more than 6 months have elapsed between the end of adjuvant and first relapse; •Neutrophils 1.5 x 109/L, Platelets 100 x 109/L, Hgb >9 g/dl. •Total bilirubin 1.5 time the upper-normal limits (UNL) of the institutional normal values and ASAT (SGOT) and/or ALAT (SGPT) 2.5 x UNL, or 5 x UNL in case of liver metastases, alkaline phosphatase 2.5 x UNL, 5 x UNL in case of liver metastases. •Creatinine clearance >50 mL/min or serum creatinine 1.5 x UNL. •Urine dipstick of proteinuria <2+. Patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must demonstrate <1 g of protein/24 hr. •Written informed consent to treatment and translational analyses.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 62
排除标准
- •Radiotherapy to any site within 4 weeks before the study. •Previous treatment with bevacizumab •Untreated brain metastases or spinal cord compression or primary brain tumours. •History or evidence upon physical examination of CNS disease unless adequately treated. ?Symptomatic peripheral neuropathy > 2 grade NCIC-CTG criteria; •Serious, non-healing wound, ulcer, or bone fracture. •Evidence of bleeding diathesis or coagulopathy. •Uncontrolled hypertension. •Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (=6 months), myocardial infarction (=6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication. •Current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes. •Chronic, daily treatment with high-dose aspirin (>325 mg/day). •Treatment with any investigational drug within 30 days prior to enrolment. •Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal and squamous cell carcinoma or cervical cancer in situ. •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study. •Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication. •Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study (barriere contraceptive measure or oral contraception).
研究者
相似试验
进行中（未招募）
不适用
未命名试验Advanced or metastatic predominantly transitional cell carcinoma of the urothelial tract.MedDRA version: 16.1Level: LLTClassification code 10046722Term: Urothelial carcinoma bladder stage IVSystem Organ Class: 100000004864EUCTR2011-000272-34-DEPIERRE FABRE MEDICAMENT77
进行中（未招募）
不适用
Study to assess the maintenance treatment with Vinflunine after a therapy with gemcitabine and cisplatin in patients with metastatic transitional cell carcinoma of the urothelial tract.EUCTR2011-000272-34-ITPIERRE FABRE MEDICAMENT77
进行中（未招募）
不适用
未命名试验EUCTR2011-000272-34-ATPIERRE FABRE MEDICAMENT77
已完成
2 期
Randomized phase 2 study comparing maintenance treatments with paclitaxel plus bevacizumab and endocrine agent in patients with inoperable or recurrent breast cancer who received prior endocrine treatment and achieved non progressive disease during induction treatment with paclitaxel plus bevacizumab.Breast cancerJPRN-UMIN000008955CAPTURE Clinical Trial Group150
尚未招募
不适用
A prospective study comparing targeted anticancer drug + irinotecan and targeted anticancer drug + 5-Fluorouracil / Leucovorin as maintenance treatment after primary induction chemotherapy for metastatic colorectal cancerNeoplasmsKCT0008619ational Cancer Center138